The Motley Fool Discussion Boards

Previous Page

Stocks E / Exelixis, Inc.


Subject:  Re: exel offering Date:  8/8/2012  11:52 PM
Author:  XMFBreakerTinker Number:  458 of 667

It is a go with the FDA. The full data set is still being produced and is not known such as overall survival. But progression free survival, if memory serves (and mine is pretty good) was 27 or 28% for CABO and 0% for placebo.

That is not a fluke. That is efficacy. If that is not efficacy, then we better redefine the term.

MTC is a small market